Given current guidelines that strongly recommend first-line treatment with targeted agents rather than immunochemotherapy for patients with sensitizing alterations in EGFR, ALK, ROS1, and BRAF10, an initial liquid biopsy assessment may be medically appropriate in many patients and could potentially reduce delays in initiation of treatment that cause anxiety in patients44. The gene discussed is EGFR; the disease is Anxiety.